{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:23:48Z","timestamp":1786973028388,"version":"build-2736575974"},"reference-count":74,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100020442","name":"Beijing Municipal Human Resources and Social Security Bureau","doi-asserted-by":"publisher","award":["2021-ZZ-004"],"award-info":[{"award-number":["2021-ZZ-004"]}],"id":[{"id":"10.13039\/501100020442","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.retram.2024.103488","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T17:16:11Z","timestamp":1733332571000},"page":"103488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["CAR-iNKT cell therapy: mechanisms, advantages, and challenges"],"prefix":"10.1016","volume":"73","author":[{"given":"Zixuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1805-6444","authenticated-orcid":false,"given":"Guangji","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.retram.2024.103488_bib0001","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev.immunol.25.022106.141711","article-title":"The biology of NKT cells","volume":"25","author":"Bendelac","year":"2007","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"10.1016\/j.retram.2024.103488_bib0002","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1158\/2326-6066.CIR-15-0098","article-title":"NKG2D receptor and its ligands in host defense","volume":"3","author":"Lanier","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"10.1016\/j.retram.2024.103488_bib0003","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00430-014-0338-1","article-title":"Increased expressions of NKp44, NKp46 on NK\/NKT-like cells are associated with impaired cytolytic function in self-limiting hepatitis E infection","volume":"203","author":"Das","year":"2014","journal-title":"Med Microbiol Immunol"},{"issue":"6","key":"10.1016\/j.retram.2024.103488_bib0004","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1248\/yakushi.129.649","article-title":"[Immunoregulation by iNKT cells]","volume":"129","author":"Miyake","year":"2009","journal-title":"Yakugaku Zasshi"},{"issue":"1","key":"10.1016\/j.retram.2024.103488_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms12010230","article-title":"Natural killer cells and cytotoxic T cells: complementary partners against microorganisms and cancer","volume":"12","author":"Vojdani","year":"2024","journal-title":"Microorganisms"},{"key":"10.1016\/j.retram.2024.103488_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.dci.2021.104330","article-title":"Swine unconventional T cells","volume":"128","author":"Wu","year":"2022","journal-title":"Dev Comp Immunol"},{"issue":"1","key":"10.1016\/j.retram.2024.103488_bib0007","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4049\/jimmunol.182.1.250","article-title":"NKG2A inhibits invariant NKT cell activation in hepatic injury","volume":"182","author":"Kawamura","year":"2009","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.retram.2024.103488_bib0008","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.molmed.2010.10.007","article-title":"NKT cell costimulation: experimental progress and therapeutic promise","volume":"17","author":"van den Heuvel","year":"2011","journal-title":"Trends Mol Med"},{"issue":"3","key":"10.1016\/j.retram.2024.103488_bib0009","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1084\/jem.180.3.1097","article-title":"An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans","volume":"180","author":"Lantz","year":"1994","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.retram.2024.103488_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/intimm\/dxp104","article-title":"The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy","volume":"22","author":"Taniguchi","year":"2010","journal-title":"Int Immunol"},{"issue":"1","key":"10.1016\/j.retram.2024.103488_bib0011","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/imr.12187","article-title":"Innate immunity in the lung regulates the development of asthma","volume":"260","author":"DeKruyff","year":"2014","journal-title":"Immunol Rev"},{"key":"10.1016\/j.retram.2024.103488_bib0012","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.molimm.2018.11.013","article-title":"Unveiling the regulation of NKT17 cell differentiation and function","volume":"105","author":"Tsagaratou","year":"2019","journal-title":"Mol Immunol"},{"issue":"2","key":"10.1016\/j.retram.2024.103488_bib0013","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.stemcr.2016.01.005","article-title":"Cellular adjuvant properties, direct cytotoxicity of Re-differentiated V\u03b124 invariant NKT-like cells from human induced pluripotent stem cells","volume":"6","author":"Kitayama","year":"2016","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.retram.2024.103488_bib0014","article-title":"Protective effects of Ganoderma lucidum spores on estradiol benzoate-induced TEC apoptosis and compromised double-positive thymocyte development","volume":"15","author":"Yang","year":"2024","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.retram.2024.103488_bib0015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/intimm\/dxad049","article-title":"ACC1-mediated fatty acid biosynthesis intrinsically controls thymic iNKT cell development","volume":"36","author":"Kanno","year":"2024","journal-title":"Int Immunol"},{"issue":"1","key":"10.1016\/j.retram.2024.103488_bib0016","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1038\/s41467-018-06646-8","article-title":"Mrp1 is involved in lipid presentation and iNKT cell activation by Streptococcus pneumoniae","volume":"9","author":"Chandra","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.retram.2024.103488_bib0017","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/s41467-021-21574-w","article-title":"Transcriptome and chromatin landscape of iNKT cells are shaped by subset differentiation and antigen exposure","volume":"12","author":"Murray","year":"2021","journal-title":"Nat Commun"},{"issue":"91","key":"10.1016\/j.retram.2024.103488_bib0018","doi-asserted-by":"crossref","first-page":"eadj5948","DOI":"10.1126\/sciimmunol.adj5948","article-title":"Non-apoptotic FAS signaling controls mTOR activation and extrafollicular maturation in human B cells","volume":"9","author":"Staniek","year":"2024","journal-title":"Sci Immunol"},{"issue":"33","key":"10.1016\/j.retram.2024.103488_bib0019","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2208522119","article-title":"Early B cell factor 4 modulates FAS-mediated apoptosis and promotes cytotoxic function in human immune cells","volume":"119","author":"Kubo","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.retram.2024.103488_bib0020","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s12016-024-08998-0","article-title":"CAR-NKT Cells in Asthma: use of NKT as a promising cell for CAR therapy","volume":"66","author":"Taheri","year":"2024","journal-title":"Clin Rev Allergy Immunol"},{"issue":"20","key":"10.1016\/j.retram.2024.103488_bib0021","first-page":"13","article-title":"The current landscape of NKT cell immunotherapy and the hills ahead","author":"Nelson","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.retram.2024.103488_bib0022","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41577-018-0034-2","article-title":"Tissue-specific functions of invariant natural killer T cells","volume":"18","author":"Crosby","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.retram.2024.103488_bib0023","article-title":"Traversing the bench to bedside journey for iNKT cell therapies","volume":"15","author":"O'Neal","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.retram.2024.103488_bib0024","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3389\/fimmu.2017.00900","article-title":"Invariant natural killer T cells as suppressors of graft-versus-host disease in allogeneic hematopoietic stem","volume":"8","author":"Mavers","year":"2017","journal-title":"Cell Transplant Front Immunol"},{"issue":"7","key":"10.1016\/j.retram.2024.103488_bib0025","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.it.2022.04.012","article-title":"Deconstructing iNKT cell development at single-cell resolution","volume":"43","author":"Baranek","year":"2022","journal-title":"Trends Immunol"},{"key":"10.1016\/j.retram.2024.103488_bib0026","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.3389\/fimmu.2017.01950","article-title":"Unraveling natural killer T-cells development","volume":"8","author":"Bennstein","year":"2017","journal-title":"Front Immunol"},{"issue":"24","key":"10.1016\/j.retram.2024.103488_bib0027","first-page":"22","article-title":"The framework for human host immune responses to four types of parasitic infections and relevant key JAK\/STAT signaling","author":"Wen","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.retram.2024.103488_bib0028","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.2741\/4279","article-title":"The role of invariant NKT cells in organ-specific autoimmunity","volume":"19","author":"Di Pietro","year":"2014","journal-title":"Front Biosci"},{"key":"10.1016\/j.retram.2024.103488_bib0029","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jaut.2018.04.001","article-title":"iNKT cells ameliorate human autoimmunity: lessons from alopecia areata","volume":"91","author":"Ghraieb","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.retram.2024.103488_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105948","article-title":"Subcutaneous administration of \u03b1-GalCer activates iNKT10 cells to promote M2 macrophage polarization and ameliorates chronic inflammation of obese adipose tissue","volume":"77","author":"Chen","year":"2019","journal-title":"Int Immunopharmacol"},{"issue":"76","key":"10.1016\/j.retram.2024.103488_bib0031","doi-asserted-by":"crossref","first-page":"eabj8760","DOI":"10.1126\/sciimmunol.abj8760","article-title":"A circulating subset of iNKT cells mediates antitumor and antiviral immunity","volume":"7","author":"Cui","year":"2022","journal-title":"Sci Immunol"},{"issue":"12","key":"10.1016\/j.retram.2024.103488_bib0032","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int J Biol Sci"},{"issue":"6","key":"10.1016\/j.retram.2024.103488_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9060614","article-title":"The evolution of cancer immunotherapy","volume":"9","author":"Khan","year":"2021","journal-title":"Vaccines"},{"issue":"586","key":"10.1016\/j.retram.2024.103488_bib0034","first-page":"13","article-title":"Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models","author":"Schneider","year":"2021","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.retram.2024.103488_bib0035","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.retram.2024.103488_bib0036","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2020.07.002","article-title":"Improving CAR T-cells: the next generation","volume":"57","author":"Marple","year":"2020","journal-title":"Semin Hematol"},{"issue":"11","key":"10.1016\/j.retram.2024.103488_bib0037","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1038\/s43018-024-00830-0","article-title":"CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms","volume":"5","author":"Zhou","year":"2024","journal-title":"Nat Cancer"},{"issue":"8","key":"10.1016\/j.retram.2024.103488_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.05.011","article-title":"Low graft invariant natural killer T-cell dose is a risk factor for cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation","volume":"28","author":"Schneidawind","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.retram.2024.103488_bib0039","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood-2012-01-404673","article-title":"Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival","volume":"120","author":"Rubio","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.retram.2024.103488_bib0040","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.retram.2024.103488_bib0041","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.ymthe.2020.06.004","article-title":"Ligand-induced degradation of a CAR permits reversible remote control of CAR T cell activity in vitro and in vivo","volume":"28","author":"Richman","year":"2020","journal-title":"Mol Ther"},{"issue":"11","key":"10.1016\/j.retram.2024.103488_bib0042","doi-asserted-by":"crossref","first-page":"12569","DOI":"10.1002\/cam4.5907","article-title":"Therapeutic effects of anti-GM2 CAR-T cells expressing IL-7 and CCL19 for GM2-positive solid cancer in xenograft model","volume":"12","author":"Sasaki","year":"2023","journal-title":"Cancer Med"},{"issue":"14","key":"10.1016\/j.retram.2024.103488_bib0043","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.retram.2024.103488_bib0044","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fphar.2014.00235","article-title":"The inducible caspase-9 suicide gene system as a \"safety switch\" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells","volume":"5","author":"Gargett","year":"2014","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.retram.2024.103488_bib0045","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/17843286.2018.1545373","article-title":"Chimeric antigen receptor T-cell therapy: design improvements and therapeutic strategies in cancer treatment","volume":"75","author":"Van Schandevyl","year":"2020","journal-title":"Acta Clin Belg"},{"issue":"1","key":"10.1016\/j.retram.2024.103488_bib0046","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1615\/CritRevOncog.2023048380","article-title":"Role of natural killer T (NKT) cells in myeloma biology and therapy","volume":"29","author":"Dhodapkar","year":"2024","journal-title":"Crit Rev Oncog"},{"issue":"4","key":"10.1016\/j.retram.2024.103488_bib0047","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"issue":"16","key":"10.1016\/j.retram.2024.103488_bib0048","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1073\/pnas.1817147116","article-title":"Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice","volume":"116","author":"Xie","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.retram.2024.103488_bib0049","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/s41467-023-37616-4","article-title":"The IgG4 hinge with CD28 transmembrane domain improves V(H)H-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer","volume":"14","author":"Li","year":"2023","journal-title":"Nat Commun"},{"issue":"586","key":"10.1016\/j.retram.2024.103488_bib0050","first-page":"13","article-title":"Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors","author":"Liu","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.retram.2024.103488_bib0051","article-title":"Context-specific synthetic T cell promoters from assembled transcriptional elements","author":"Appelbaum","year":"2023","journal-title":"Res Sq"},{"issue":"1","key":"10.1016\/j.retram.2024.103488_bib0052","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","article-title":"Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy","volume":"12","author":"Han","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"21","key":"10.1016\/j.retram.2024.103488_bib0053","doi-asserted-by":"crossref","first-page":"eaaz3223","DOI":"10.1126\/sciadv.aaz3223","article-title":"Chimeric antigen receptor signaling: functional consequences and design implications","volume":"6","author":"Lindner","year":"2020","journal-title":"Sci Adv"},{"issue":"2","key":"10.1016\/j.retram.2024.103488_bib0054","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.febslet.2013.11.030","article-title":"Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy","volume":"588","author":"Ahmed","year":"2014","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.retram.2024.103488_bib0055","first-page":"1","article-title":"GD2 CAR T cells against human glioblastoma","volume":"5","author":"Prapa","year":"2021","journal-title":"npj Precis Oncol"},{"issue":"23","key":"10.1016\/j.retram.2024.103488_bib0056","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-19-0421","article-title":"NKT cells coexpressing a GD2-specific chimeric antigen receptor and IL15 show enhanced in vivo persistence and antitumor activity against Neuroblastoma","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.retram.2024.103488_bib0057","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","article-title":"Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.retram.2024.103488_bib0058","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","article-title":"Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results","volume":"29","author":"Heczey","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.retram.2024.103488_bib0059","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ccell.2018.08.017","article-title":"Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting","volume":"34","author":"Rotolo","year":"2018","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.retram.2024.103488_bib0060","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007798","article-title":"Neuroblastoma: an ongoing cold front for cancer immunotherapy","volume":"11","author":"Kennedy","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.retram.2024.103488_bib0061","article-title":"CAR products from novel sources: a new avenue for the breakthrough in cancer immunotherapy","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.retram.2024.103488_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108597","article-title":"IL-21-armored B7H3 CAR-iNKT cells exert potent antitumor effects","volume":"27","author":"Liu","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.retram.2024.103488_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106942","article-title":"Novel mesothelin-targeted chimeric antigen receptor-modified UNKT cells are highly effective in inhibiting tumor progression","volume":"197","author":"Jiang","year":"2023","journal-title":"Pharmacol Res"},{"issue":"8","key":"10.1016\/j.retram.2024.103488_bib0064","first-page":"19","article-title":"The generation of CAR-transfected natural killer T cells for the immunotherapy of melanoma","author":"Simon","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.retram.2024.103488_bib0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22031096","article-title":"Preclinical evaluation of invariant natural killer T cells modified with CD38 or BCMA chimeric antigen receptors for multiple myeloma","volume":"22","author":"Poels","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.retram.2024.103488_bib0066","doi-asserted-by":"crossref","first-page":"10082","DOI":"10.1038\/s41598-023-36468-8","article-title":"The effect of blocking immune checkpoints LAG-3 and PD-1 on human invariant Natural Killer T cell function","volume":"13","author":"Balasko","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.retram.2024.103488_bib0067","doi-asserted-by":"crossref","first-page":"36962","DOI":"10.1038\/srep36962","article-title":"Soluble \u03b3c cytokine receptor suppresses IL-15 signaling and impairs iNKT cell development in the thymus","volume":"6","author":"Park","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.retram.2024.103488_bib0068","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41232-023-00275-5","article-title":"Regeneration of invariant natural killer T (iNKT) cells: application of iPSC technology for iNKT cell-targeted tumor immunotherapy","volume":"43","author":"Aoki","year":"2023","journal-title":"Inflamm Regen"},{"issue":"9","key":"10.1016\/j.retram.2024.103488_bib0069","article-title":"Generation of dual-attribute iTNK cells from hPSCs for cancer immunotherapy","volume":"4","author":"Zhang","year":"2024","journal-title":"Cell Rep Methods"},{"issue":"11","key":"10.1016\/j.retram.2024.103488_bib0070","article-title":"Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy","volume":"2","author":"Li","year":"2021","journal-title":"Cell Rep Med"},{"issue":"8","key":"10.1016\/j.retram.2024.103488_bib0071","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","article-title":"CAR T cell combination therapies to treat cancer","volume":"42","author":"Uslu","year":"2024","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.retram.2024.103488_bib0072","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.4049\/jimmunol.0803648","article-title":"PD-1\/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells","volume":"182","author":"Parekh","year":"2009","journal-title":"J Immunol"},{"issue":"45","key":"10.1016\/j.retram.2024.103488_bib0073","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201903462","article-title":"Boosting interleukin-12 antitumor activity and synergism with immunotherapy by targeted delivery with isoDGR-tagged nanogold","volume":"15","author":"Gasparri","year":"2019","journal-title":"Small"},{"issue":"1","key":"10.1016\/j.retram.2024.103488_bib0074","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41467-023-44310-y","article-title":"IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity","volume":"15","author":"Landoni","year":"2024","journal-title":"Nat Commun"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318624000503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318624000503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T07:52:14Z","timestamp":1744876334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318624000503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2452318624000503"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2024.103488","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-iNKT cell therapy: mechanisms, advantages, and challenges","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2024.103488","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103488"}}